Showing results for:
6-Thioguanine is FDA approved for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
Tabloid® Thioguanine 6-Thioguanine
Abatacept is a indicated for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.
Orencia® Abatacept
Acalabrutinib is a kinase inhibitor indicated:In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).For the treatment of adult patients with MCL who have received at least one prior therapy.For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Calquence® Acalabrutinib
Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).
Campath® Alemtuzumab
Anagrelide hydrochloride is FDA approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to improve associated symptoms including thrombo-hemorrhagic events (a process that involves either a blood clot or bleeding, such as a heart attack or stroke).
Agrylin® Anagrelide hydrochloride
Arsenic trioxide is FDA approved:For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RARA gene expression.In combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or the PML/RARA gene expression.
Trisenox® Arsenic trioxide
Asciminib is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).Previously treated Ph+ CML in CP.Ph+ CML in CP with the T315I mutation.
Scemblix® Asciminib
Asparaginase is FDA approved in combination with chemotherapy to treat people who have acute lymphoblastic leukemia.
Asparaginase
Asparaginase erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
Erwinaze® Asparaginase Erwinia chrysanthemi
Asparaginase erwinia chrysanthemi (recombinant)- rywn
Rylaze® is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Asparaginase erwinia chrysanthemi (recombinant)- rywn Rylaze®
Ayvakit® is indicated for the treatment of:Advanced Systemic Mastocytosis (AdvSM)The treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), and mast cell leukemia (MCL).Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 X 109 /L Indolent Systemic Mastocytosis (ISM)The treatment of adult patients with ISM.Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 X 109 /L
Ayvakit® Avapritinib
Axatilimab-csfr is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (about 88 pounds).
Axatilimab-csfr Niktimvo™
Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Limitations of Use: YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma. Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Yescarta® Axicabtagene ciloleucel
Vidaza® is FDA approved to treatAdult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1.1) Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).
Vidaza® Azacitidine Onureg®
Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Blenrep Belantamab mafodotin-blmf
Belinostat is FDA approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Beleodaq™ Belinostat
Rezurock™ is approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Rezurock™ Belumosudil
Bendamustine hydrochloride is FDA approved to treat people who have:Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Treanda® Bendamustine hydrochloride Bendeka™
Bexarotene is FDA approved to treat people who have skin problems arising from cutaneous T-cell lymphoma (CTCL) in patients who are refractory for at least one prior systemic therapy. It may be used after other drugs have been tried and the tumor is still a problem.
Targretin® Bexarotene
Bleomycin is FDA approved as a single agent or in proven combinations to treat people who have Hodgkin and non-Hodgkin lymphoma. Bleomycin may cause a temporary loss of hair in some people. Normal hair growth should return after treatment ends (although it may take several months).
Blenoxane® Bleomycin
Blinatumomab is FDA approved for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
Blincyto® Blinatumomab
Bortezomib is FDA approved to treat people with myeloma and for the retreatment of adult patients with myeloma who had previously responded to bortezomib therapy and relapsed at least six months following completion of prior bortezomib treatment. Bortezomib is also approved to treat people with previously untreated mantle cell lymphoma as well as patients who have received at least one prior therapy.
Velcade® Bortezomib
Bosutinib is FDA approved for the treatment ofAdult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Bosulif® Bosutinib
Brentuximab vedotin is FDA approved for the treatment of:Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral Tcell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone.Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.
Adcetris® Brentuximab vedotin
Brexucabtagene autoleucel is FDA approved for the treatment ofAdult patients with relapsed or refractory mantle cell lymphoma (MCL).This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Tecartus® Brexucabtagene autoleucel
Busulfan is FDA approved in combination with cyclophosphamide as a conditioning regimen prior to allogeneic stem cell transplantation for people who have chronic myeloid leukemia.
Busulfex® Myleran® Busulfan
Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Asparlas® Calaspargase pegol-mknl
Carboplatin is FDA approved to treat people who have certain kinds of cancer, including some blood cancers. Carboplatin may cause temporary loss of hair during treatment. Normal hair growth should return after treatment ends.
Paraplatin® Carboplatin
Carfilzomib is indicated in combination withLenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. It is also indicated as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.In a clinical study of relapsed multiple myeloma, carfilzomib and dexamethasone kept the disease from getting worse longer than bortezomib and dexamethasone (median of 18.7 months compared with 9.4 months) and helped patients live longer (median of 47.6 months compared with 40 months).Daratumumab (Darzalex®) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.
Kyprolis® Carfilzomib
Carmustine is FDA approved to treat people who have myeloma (in combination with prednisone); relapsed or refractory Hodgkin lymphoma (as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy or who fail to respond to primary therapy); relapsed or refractory non-Hodgkin lymphoma (as secondary therapy in combination with other approved drugs).
BiCNU® BCNU Carmustine
Chlorambucil is FDA approved to treat people who have chronic lymphocytic leukemia (CLL), some types of non-Hodgkin lymphoma and advanced Hodgkin lymphoma.
Leukeran® Chlorambucil
Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Carvykti™ Ciltacabtagene autoleucel
Cisplatin is FDA approved alone or in combination with other drugs to treat people who have certain types of cancer.
Platinol®-AQ Cisplatin
Cladribine is FDA approved to treat people who have active hairy cell leukemia. It is also used to treat some other types of leukemia and lymphoma.
Leustatin® 2-CdA Cladribine
Clofarabine is FDA approved to treat children and young adults (1- 21 years old) with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Clolar® Clofarabine
Cobimetinib is indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.
Cobimetinib Cotellic®
Copanlisib is FDA approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Aliqopa® Copanlisib
Dexamethasone, hydrocortisone, methylprednisolone and prednisone are FDA approved corticosteroids that are used to treat many medical problems, including some kinds of cancer.
Decadron ®
Crizotinib is FDA approved for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.Limitations of Use: The safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Xalkori® Crizotinib
Cyclophosphamide is FDA approved to treat several types of cancer, including people who have Hodgkin lymphoma, non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute and chronic myeloid leukemia, myeloma, and mycosis fungoides. Cyclophosphamide is usually used in combination with other drugs.Cyclophosphamide may cause a temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Cytoxan® Cyclophosphamide